Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 11/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638428 | 0.83 | DRD4 (0.52) | DRD2DRD3CXCR4DRD4 | |
| SCHEMBL12416774 | 0.83 | CXCR4 (0.59) | METTL3DRD2DRD3CXCR4EGLN1 | |
| SCHEMBL1638247 | 0.77 | METTL3 (0.41) | METTL3DRD2DRD3CXCR4EGLN1 | |
| SCHEMBL1638530 | 0.74 | METTL3 (0.45) | METTL3DRD2DRD3EGLN1DRD4 | |
| SCHEMBL1205965 | 0.73 | CXCR4 (0.56) | DRD2DRD3CXCR4DRD4 | |
| SCHEMBL12762549 | 0.71 | CXCR4 (0.43) | METTL3DRD2DRD3CXCR4EGLN1 | |
| SCHEMBL12426518 | 0.70 | CXCR4 (0.49) | CXCR4 | |
| SCHEMBL2201359 | 0.70 | CXCR4 (0.47) | CXCR4 | |
| SCHEMBL12894265 | 0.69 | CXCR4 (0.65) | DRD2DRD3CXCR4DRD4 | |
| SCHEMBL2201355 | 0.68 | KMT2A (0.45) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | METTL3 784/4885DRD2 175/4885DRD3 283/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | METTL3 2082/4885DRD2 257/4885DRD3 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.